Adolfo DÃez-PÃ©rez

List of Publications by Year
in descending order

149 papers	9,086 citations	50276 46 h-index	43889 91 g-index
152 all docs	152 docs citations	152 times ranked	9313 citing authors

#	Article	IF	Citations
1	Romosozumab in Postmenopausal Women with Low Bone Mineral Density. New England Journal of Medicine, 2014, 370, 412-420.	27.0	981
2	Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Annals of the Rheumatic Diseases, 2014, 73, 1659-1664.	0.9	559
3	Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW. American Journal of Medicine, 2011, 124, 1043-1050.	1.5	446
4	A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women. Journal of Bone and Mineral Research, 2014, 29, 223-233.	2.8	388
5	The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women. Journal of Bone and Mineral Research, 2012, 27, 294-300.	2.8	261
6	Microindentation for in vivo measurement of bone tissue mechanical properties in humans. Journal of Bone and Mineral Research, 2010, 25, 1877-1885.	2.8	237
7	The Association between Common Vitamin D Receptor Gene Variations and Osteoporosis: A Participant-Level Meta-Analysis. Annals of Internal Medicine, 2006, 145, 255.	3.9	219
8	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas, 2014, 79, 122-132.	2.4	213
9	Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study. Journal of Bone and Mineral Research, 2005, 20, 1514-1524.	2.8	206
10	Relationship of Weight, Height, and Body Mass Index With Fracture Risk at Different Sites in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women (GLOW). Journal of Bone and Mineral Research, 2014, 29, 487-493.	2.8	192
11	Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk. Journal of Bone and Mineral Research, 2003, 19, 394-401.	2.8	190
12	Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review. Bone, 2014, 58, 126-135.	2.9	172
13	Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. Calcified Tissue International, 2011, 89, 91-104.	3.1	170
14	Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study. PLoS Medicine, 2006, 3, e90.	8.4	160
15	Impact of Prevalent Fractures on Quality of Life: Baseline Results From the Global Longitudinal Study of Osteoporosis in Women. Mayo Clinic Proceedings, 2010, 85, 806-813.	3.0	159
16	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. Journal of Bone and Mineral Research, 2018, 33, 1397-1406.	2.8	144
17	Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. Journal of Bone and Mineral Research, 2012, 27, 645-653.	2.8	143
18	Relationship Between Bone Quantitative Ultrasound and Fractures: A Meta-Analysis. Journal of Bone and Mineral Research, 2006, 21, 1126-1135.	2.8	130

#	ARTICLE	IF	CITATIONS
19	Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. Journal of Bone and Mineral Research, 2013, 28, 162-168.	2.8	130
20	Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone, 2012, 50, 1288-1293.	2.9	129
21	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. Journal of Bone and Mineral Research, 2017, 32, 3-10.	2.8	127
22	HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort study. Journal of Bone and Mineral Research, 2013, 28, 1259-1263.	2.8	115
23	The association between fracture site and obesity in men: A population-Based cohort study. Journal of Bone and Mineral Research, 2013, 28, 1771-1777.	2.8	103
24	Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis International, 2006, 17, 313-316.	3.1	94
25	Two New Single-Nucleotide Polymorphisms in the COL1A1 Upstream Regulatory Region and Their Relationship to Bone Mineral Density. Journal of Bone and Mineral Research, 2002, 17, 384-393.	2.8	91
26	Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. Journal of Cellular Biochemistry, 2007, 101, 1430-1438.	2.6	80
27	Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Research and Treatment, 2011, 125, 869-878.	2.5	80
28	Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone, 2011, 49, 493-498.	2.9	78
29	Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis. Journal of Bone and Mineral Research, 2015, 30, 1651-1656.	2.8	78
30	Probability of fractures predicted by FRAXÂ® and observed incidence in the Spanish ECOSAP Study cohort. Bone, 2012, 50, 373-377.	2.9	76
31	An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Annals of the Rheumatic Diseases, 2013, 72, 911-917.	0.9	76
32	Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone, 2019, 120, 1-8.	2.9	75
33	Ankylosing Spondylitis Is Associated With an Increased Risk of Vertebral and Nonvertebral Clinical Fractures: A Population-Based Cohort Study. Journal of Bone and Mineral Research, 2014, 29, 1770-1776.	2.8	70
34	MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones. BMC Medical Genomics, 2016, 8, 75.	1.5	67
35	Risk factors for prediction of inadequate response to antiresorptives. Journal of Bone and Mineral Research, 2012, 27, 817-824.	2.8	63
36	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e83306.	2.5	63

#	Article	IF	Citations
37	Obesity and the Relative Risk of Knee Replacement Surgery in Patients With Knee Osteoarthritis: A Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 817-825.	5.6	61
38	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, 36, 2811-2824.	2.9	60
39	Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. Journal of Medical Devices, Transactions of the ASME, 2013, 7, 410051-410056.	0.7	59
40	Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. European Journal of Endocrinology, 2003, 148, 519-526.	3.7	58
41	Predicting fractures in an international cohort using risk factor algorithms without BMD. Journal of Bone and Mineral Research, 2011, 26, 2770-2777.	2.8	58
42	Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the artâ€"outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2019, 31, 1375-1389.	2.9	53
43	Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas, 2010, 66, 291-297.	2.4	50
44	<i>GGPS1</i> Mutation and Atypical Femoral Fractures with Bisphosphonates. New England Journal of Medicine, 2017, 376, 1794-1795.	27.0	50
45	Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population-Based Cohort Study. Journal of Bone and Mineral Research, 2014, 29, 268-274.	2.8	48
46	Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW). Journal of Bone and Mineral Research, 2014, 29, 260-267.	2.8	47
47	Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis. Journal of Bone and Mineral Research, 2020, 36, 820-832.	2.8	46
48	Official Positions for FRAXÂ® Bone Mineral Density and FRAXÂ® Simplification. Journal of Clinical Densitometry, 2011, 14, 226-236.	1.2	45
49	Relationship Between Mortality and BMI After Fracture: A Population-Based Study of Men and Women Aged â‰¥40 Years. Journal of Bone and Mineral Research, 2014, 29, 1737-1744.	2.8	45
50	Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis. Scientific Reports, 2017, 7, 3781.	3.3	44
51	Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO. Quality of Life Research, 2001, 10, 307-317.	3.1	42
52	Evaluation of Calcaneal Quantitative Ultrasound in a Primary Care Setting as a Screening Tool for Osteoporosis in Postmenopausal Women. Journal of Clinical Densitometry, 2003, 6, 237-245.	1.2	42
53	Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties?. Journal of Bone and Mineral Research, 2015, 30, 1784-1789.	2.8	42
54	Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast, 2012, 21, 95-101.	2.2	40

#	ARTICLE	IF	CITATIONS
55	Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporosis International, 2006, 17, 1-7.	3.1	39
56	Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. JAMA - Journal of the American Medical Association, 2021, 326, 1504.	7.4	38
57	Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Research and Treatment, 2013, 140, 385-395.	2.5	37
58	In vitro functional assay of alleles and haplotypes of two -promoter SNPs. Bone, 2005, 36, 902-908.	2.9	36
59	Bone mass loss after sleeve gastrectomy: A prospective comparative study with gastric bypass. CirugÃa EspaÃ±ola (English Edition), 2010, 88, 103-109.	0.1	36
60	Characteristics associated with anti-osteoporosis medication use: Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. Bone, 2012, 51, 975-980.	2.9	36
61	Obesity, Health-Care Utilization, and Health-Related Quality of Life After Fracture in Postmenopausal Women: Global Longitudinal Study of Osteoporosis in Women (GLOW). Calcified Tissue International, 2014, 94, 223-231.	3.1	36
62	Brief Report: HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 314-318.	2.1	35
63	Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation. European Journal of Endocrinology, 2005, 153, 981-988.	3.7	34
64	Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study. Breast Cancer Research and Treatment, 2012, 133, 1159-1167.	2.5	34
65	Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 2022, 34, 695-714.	2.9	33
66	Promoter 2 -1025 T/C Polymorphism in the RUNX2 Gene Is Associated with Femoral Neck BMD in Spanish Postmenopausal Women. Calcified Tissue International, 2007, 81, 327-332.	3.1	32
67	Increased hip fracture and mortality in chronic kidney disease individuals: The importance of competing risks. Bone, 2015, 73, 154-159.	2.9	31
68	Bone Density, Microarchitecture, and Tissue Quality Long-term After Kidney Transplant. Transplantation, 2017, 101, 1290-1294.	1.0	31
69	Clinical experience with microindentation in vivo in humans. Bone, 2017, 95, 175-182.	2.9	30
70	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. Journal of Bone and Mineral Research, 2016, 31, 1466-1472.	2.8	29
71	Real-Life and RCT Participants: Alendronate Users Versus FITsâ€™ Trial Eligibility Criterion. Calcified Tissue International, 2016, 99, 243-249.	3.1	29
72	Radiofrequency Echographic Multi Spectrometry (REMS) for the diagnosis of osteoporosis in a European multicenter clinical context. Bone, 2021, 143, 115786.	2.9	29

#	Article	IF	Citations
73	Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity. Journal of Rheumatology, 2007, 34, 1823-6.	2.0	29
74	A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. Bone, 2006, 38, 738-743.	2.9	27
75	Effect of IL‑1β, PGE$_2$, and TGF‑β1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts. Journal of Cellular Biochemistry, 2010, 110, 304-310.	2.6	27
76	Socioeconomic status and its association with the risk of developing hip fractures: A region-wide ecological study. Bone, 2015, 73, 127-131.	2.9	27
77	Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies. Calcified Tissue International, 2016, 98, 359-369.	3.1	27
78	Differential Mortality and the Excess Rates of Hip Fracture Associated With Type 2 Diabetes: Accounting for Competing Risks in Fracture Prediction Matters. Journal of Bone and Mineral Research, 2018, 33, 1417-1421.	2.8	27
79	Calcium Citrate and Vitamin D in the Treatment of Osteoporosis. Clinical Drug Investigation, 2011, 31, 285-298.	2.2	26
80	Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 322-327.	2.1	26
81	Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. Aids, 2018, 32, 913-920.	2.2	26
82	Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. Bone, 2004, 35, 1164-1168.	2.9	25
83	Analysis of Three Functional Polymorphisms in Relation to Osteoporosis Phenotypes: Replication in a Spanish Cohort. Calcified Tissue International, 2010, 87, 14-24.	3.1	25
84	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. Journal of Antimicrobial Chemotherapy, 2015, 70, 2104-2107.	3.0	25
85	Hospital-at-Home Expands Hospital Capacity During COVID-19 Pandemic. Journal of the American Medical Directors Association, 2021, 22, 939-942.	2.5	24
86	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 2016, 28, 1-16.	2.9	22
87	Selective estrogen receptor modulators (SERMS). Arquivos Brasileiros De Endocrinologia E Metabologia, 2006, 50, 720-734.	1.3	21
88	Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types. Journal of Bone and Mineral Research, 2018, 33, 2091-2098.	2.8	21
89	Impact microindentation in men with impaired fasting glucose and type 2 diabetes. Bone, 2021, 142, 115685.	2.9	21
90	Feasibility and tolerability of bone impact microindentation testing: a cross-sectional, population-based study in Australia. BMJ Open, 2018, 8, e023959.	1.9	20

#	Article	IF	Citations
91	Pro-osteoporotic miR-320a impairs osteoblast function and induces oxidative stress. PLoS ONE, 2018, 13, e0208131.	2.5	20
92	Ataxic form of central pontine myelinolysis. Lancet Neurology, The, 2002, 1, 517-518.	10.2	19
93	Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index. Bone, 2017, 103, 64-69.	2.9	19
94	Bisphosphonates. Maturitas, 2002, 43, 19-26.	2.4	18
95	A Haplotype-Based Analysis of the <i>LRP5</i> Gene in Relation to Osteoporosis Phenotypes in Spanish Postmenopausal Women. Journal of Bone and Mineral Research, 2008, 23, 1954-1963.	2.8	18
96	Mortality, Falls, and Fracture Risk Are Positively Associated With Frailty: A SIDIAP Cohort Study of 890 000 Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 148-154.	3.6	18
97	<i>COL1A1</i> haplotypes and hip fracture. Journal of Bone and Mineral Research, 2012, 27, 950-953.	2.8	17
98	SNPs in bone-related miRNAs are associated with the osteoporotic phenotype. Scientific Reports, 2017, 7, 516.	3.3	17
99	Baseline observations from the POSSIBLE EUÂ® study: characteristics of postmenopausal women receiving bone loss medications. Archives of Osteoporosis, 2010, 5, 61-72.	2.4	16
100	Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. Journal of Bone and Mineral Research, 2016, 31, 234-244.	2.8	16
101	Bone metabolism and histomorphometric changes in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2002, 31, 285-290.	1.1	15
102	Expression profiling of microRNAs in human bone tissue from postmenopausal women. Human Cell, 2018, 31, 33-41.	2.7	15
103	Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates. Journal of Bone and Mineral Research, 2020, 35, 291-297.	2.8	15
104	Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly. Endocrine Connections, 2019, 8, 39-49.	1.9	15
105	Functional relevance of the BMD-associated polymorphism rs312009: Novel Involvement of RUNX2 in <i>LRP5</i> transcriptional regulation. Journal of Bone and Mineral Research, 2011, 26, 1133-1144.	2.8	14
106	Genetic Analysis of High Bone Mass Cases from the BARCOS Cohort of Spanish Postmenopausal Women. PLoS ONE, 2014, 9, e94607.	2.5	14
107	Empirically Based Composite Fracture Prediction Model From the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). Journal of Clinical Endocrinology and Metabolism, 2014, 99, 817-826.	3.6	14
108	Common and rare variants of WNT16, DKK1 and SOST and their relationship with bone mineral density. Scientific Reports, 2018, 8, 10951.	3.3	14

#	Article	IF	Citations
109	Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study. Breast Cancer Research and Treatment, 2019, 177, 53-60.	2.5	14
110	Validation of fragility fractures in primary care electronic medical records: A population-based study. ReumatologÃa ClÃnica, 2019, 15, e1-e4.	0.5	14
111	Bone material strength index is associated with prior fracture in men with and without moderate chronic kidney disease. Bone, 2020, 133, 115241.	2.9	14
112	Current and future treatments of secondary osteoporosis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 885-894.	4.7	13
113	Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. Current Medical Research and Opinion, 2015, 31, 767-777.	1.9	13
114	Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation. Journal of Bone and Mineral Research, 2017, 32, 1575-1581.	2.8	13
115	Associations Between Bone Impact Microindentation and Clinical Risk Factors for Fracture. Endocrinology, 2019, 160, 2143-2150.	2.8	13
116	Functional characterization of the C7ORF76 genomic region, a prominent GWAS signal for osteoporosis in 7q21.3. Bone, 2019, 123, 39-47.	2.9	12
117	Comparison of the Effects of Ossein-Hydroxyapatite Complex and Calcium Carbonate on Bone Metabolism in Women with Senile Osteoporosis. Clinical Drug Investigation, 2011, 31, 817-824.	2.2	11
118	Analyses of <i>RANK</i> and <i>RANKL</i> in the Post-GWAS Context: Functional Evidence of Vitamin D Stimulation Through a <i>RANKL</i> Distal Region. Journal of Bone and Mineral Research, 2013, 28, 2550-2560.	2.8	11
119	Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpressSR (OSTEOXPRESS Study). Aging Clinical and Experimental Research, 2010, 22, 419-426.	2.9	10
120	Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090966.	3.2	10
121	Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. AIDS Research and Treatment, 2016, 2016, 1-8.	0.7	9
122	Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report. Bone Reports, 2017, 6, 81-86.	0.4	9
123	Bone health evaluation one year after aromatase inhibitors completion. Bone, 2018, 117, 54-59.	2.9	9
124	Maintenance low dose systemic glucocorticoids have limited impact on bone strength and mineral density among incident renal allograft recipients: A pilot prospective cohort study. Bone, 2018, 116, 290-294.	2.9	9
125	Oral Bisphosphonate Use and Allâ€Cause Mortality in Patients With Moderateâ€"Severe (Grade 3Bâ€5D) Chronic Kidney Disease: A Populationâ€Based Cohort Study. Journal of Bone and Mineral Research, 2020, 35, 894-900.	2.8	8
126	Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. Maturitas, 2015, 82, 402-410.	2.4	7

#	Article	IF	Citations
127	Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort. PLoS ONE, 2018, 13, e0203533.	2.5	7
128	Functional Analyses of Four CYP1A1 Missense Mutations Present in Patients with Atypical Femoral Fractures. International Journal of Molecular Sciences, 2021, 22, 7395.	4.1	6
129	Patterns of Anti-Osteoporosis Medication Use among Women at High Risk of Fracture: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e82840.	2.5	6
130	Associations between Bone Material Strength Index, Calcaneal Quantitative Ultrasound, and Bone Mineral Density in Men. Journal of the Endocrine Society, 2021, 5, bvaa179.	0.2	6
131	Proof of Concept on Functionality Improvement of Mesenchymal Stem-Cells, in Postmenopausal Osteoporotic Women Treated with Teriparatide (PTH1-34), After Suffering Atypical Fractures. Calcified Tissue International, 2019, 104, 631-640.	3.1	5
132	Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine. Journal of Antimicrobial Chemotherapy, 2020, 75, 2998-3003.	3.0	5
133	Functional Assessment of Coding and Regulatory Variants From the <scp><i>DKK1</i></scp> Locus. JBMR Plus, 2020, 4, e10423.	2.7	5
134	Bone tissue quality in patients with monoclonal gammopathy of uncertain significance. Journal of Bone and Mineral Metabolism, 2020, 38, 563-569.	2.7	5
135	AI-related BMD variation in actual practice conditions: A prospective cohort study. Endocrine-Related Cancer, 2016, 23, 303-312.	3.1	4
136	Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women. Maturitas, 2018, 116, 83-88.	2.4	4
137	Normative Data for Impact Microindentation for Australian Men: Cross‐Sectional Data From the Geelong Osteoporosis Study. JBMR Plus, 2020, 4, e10384.	2.7	4
138	Is there a future for selective estrogen-receptor modulators in osteoporosis?. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 55-59.	2.7	3
139	Tuberculosis: Plasma levels of vitamin D and its relation with infection and disease. Medicina Clãnica (English Edition), 2015, 144, 111-114.	0.2	3
140	Avances en la valoraciã³n de la salud ã³sea en el trasplantado renal. Nefrologia, 2018, 38, 27-33.	0.4	3
141	Associations between parameters of peripheral quantitative computed tomography and bone material strength index. Bone, 2022, 155, 116268.	2.9	3
142	Development and external validation of a 1- and 5-year fracture prediction tool based on electronic medical records data: The EPIC risk algorithm. Bone, 2022, 162, 116469.	2.9	3
143	Erratum to â€œThe role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)â€•[Maturitas 79 (2014) 122â€"132]. Maturitas, 2015, 80, 337.	2.4	2
144	Advances in the evaluation of bone health in kidney transplant patients. Nefrologia, 2018, 38, 27-33.	0.4	2

#	Article	IF	Citations
145	Teriparatide for Glucocorticoid-induced Osteoporosis. Journal of Rheumatology, 2012, 39, 461-462.	2.0	1
146	Octodon degus, a new model to study the agonist and plexus-induced response in the urinary bladder. Journal of Physiology and Biochemistry, 2017, 73, 77-87.	3.0	1
147	Cortical and Trabecular Bone Analysis of Patients With High Bone Mass From the Barcelona Osteoporosis Cohort Using 3-Dimensional Dual-Energy X-ray Absorptiometry: A Case-Control Study. Journal of Clinical Densitometry, 2018, 21, 480-484.	1.2	1
148	Effect of the Tumor Suppressor miR-320a on Viability and Functionality of Human Osteosarcoma Cell Lines Compared to Primary Osteoblasts. Applied Sciences (Switzerland), 2020, 10, 2852.	2.5	1
149	Validation of fragility fractures in primary care electronic medical records: A population-based study. ReumatologÃa ClÃnica (English Edition), 2019, 15, e1-e4.	0.3	0